Evolocumab for PCSK9 Lowering in Early Acute Sepsis (The PLEASe Study)
Status:
Recruiting
Trial end date:
2021-02-11
Target enrollment:
Participant gender:
Summary
This study evaluates using evolocumab, a currently approved and marketed biologic drug, in a
novel way. Patients who present to the emergency room or intensive care unit (ICU) with
severe infection are eligible. Either the patient or their designated decision maker will be
approached for consent. If they choose to participate they will be given either a single dose
of evolocumab, a higher single dose of evolocumab,or a single dose of placebo. Participants
will be followed during their stay in the ICU and will receive follow up phone calls at Day
28 and 90.